| NIH P30 CFRTC | Sid Venkatesh, PhD
ISB and Microbiology | 2025-27 | Microbiome-targeted Diets for Rectifying GI Dysfunction in People with Cystic Fibrosis |
| NIH P30 CFRTC | Anne Manicone, MD
Medicine, Pulmonary | 2024-26 | Identifying Novel Compounds to Polarize Macrophages toward Reparative States |
| NIH P30 CFRTC | Vincenzo Cirulli, PhD
Medicine, Metabolism | 2024-26 | Derivation of Functional Islet Tissue from CF Patient-derived iPSC |
| CFF RDP | Jim Bruce, PhD
Genome Sciences | 2024-26 | Investigation of the diagnostic potential of P. aeruginosa protein levels in blood and urine |
| CFF RDP | Dustin Long, MD
Anesthesiology | 2024-26 | Diagnostic Utility of mRNA for Characterizing Heteroresistant P. aeruginosa Population Response to Antibiotic Treatment |
| CFF RDP | Tom Hawn, MD, PhD
Allergy & Infectios Dis | 2024-25 | Non-tuberculous Mycobacteria & Cystic Fibrosis |
| NIH P30 CFRTC | Patrick Mitchell, PhD
Microbiology | 2022-25 | CFTR deficiency modulates epithelial inflammasomes |
| NIH P30 CFRTC | Jarrad Scarlett, MD, PhD, Peds Gastroenterology | 2022-25 | Role of dysfunctional gut-brain signaling in the pathogenesis of cystic fibrosis-related diabetes |
| NIH P30 CFRTC | William Grady, MD
Neel Dey, MD
Gastroenterology | 2022-25 | Colonic inflammation and dysbiosis: Factors that induce colorectal cancer (CRC) in cystic fibrosis |
| CFF RDP | Alison Feder, PhD
Genome Sciences | 2022-25 | Evolutionary and mutational drivers of P. aeruginosa persistence through Trikafta |
| CFF RDP | Waleed Abuzeid, MD
Otolaryngology | 2020-25 | Disruption of P. aeruginosa biofilms using a novel nitric oxide-releasing nanoparticle |
| NH P30 CFRTC | Edward Kelly, PhD
Pharmaceutics
| 2020-25 | CF kidney phenotype and potential consequences in the era of CFTR correction |
